30 closest matches · ranked by relevance
Yellow Fever
Primary: The Incidence and Severity of Adverse Events in Each Treatment Group in the Double-blind Treatment Period up to 42 Days Post-vaccination. — 13; 13; 2; 22 participants
Dengue
Primary: Percentage of Participants Who Are YF and Dengue Virus (DENV)-Naive at Baseline and Are Seroprotected Against YF on Day 30 as Measured by Plaque Reduction Neutralization…
Atopic Dermatitis
Primary: Comparison of Anti-YF Antibody Levels by Measurement of Log10 Neutralization Index (LNI): YFV-17D TC- (AD) Participants Compared to YFV-17D TC- (Non-AD) Participants…
Dengue · Dengue Hemorrhagic Fever · Yellow Fever
Primary: Percentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly…
Yellow Fever Vaccination Reaction
Primary: Adverse Events — 26; 27; 28 Participants
Yellow Fever
Primary: Occurrence of All Serious Adverse Events (SAEs) at Any Time During the Study — 0; 0; 0 Serious Adverse Event
Japanese Encephalitis · Yellow Fever
Primary: Number of Participants With Japanese Encephalitis Seroconversion Following ChimeriVax™-JE or STAMARIL® Alone or the Co-administration of ChimeriVax™-JE and STAMARIL®, or…
Yellow Fever
Primary: Peak Neutralizing Antibody Titer — 1.37 Log YF antibody titer
Ebolavirus Disease
Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml
Japanese Encephalitis
Primary: Percentage of Participants With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 98.0; 99.3; 100.0; 100.0 percentage of participants
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2 — 5.38…
Dengue Fever · Zika · Vector-Borne Diseases
Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants
Ebola Virus
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-EBO S Vaccine Administration — 3; 3; 6; 16 Participants
Japanese Encephalitis
Primary: Primary: Plasmablast Percentage of Total B Cells at 7 Days Post Vaccine — 1.36; 1.96; 1.69 percent plasmablasts of B cells
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Percentage of Participants (Aged 2 to 11 Years) Reporting Solicited Injection-site and Systemic Reactions Following Each Injection (Inj.) With CYD Dengue Vaccine or…
Malaria · Plasmodium Falciparum Malaria
Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events
Chikungunya
Primary: Number of Participants With AEs and Abnormal Lab Values, Vital Signs, and PE Findings — 11; 13; 4; 4 subjects
Dengue
Primary: Percentage of Subjects With Seropositivity Rates for Antibodies to DEN-1 - DEN-4 (ATP Cohort for Immunogenicity) — 16.7; 83.3; 16.7; 66.7 % of subjects
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 0; 1 Participants
Rift Valley Fever
Primary: Safety: All Incidences of Erythema — 15; 10; 0 number of events
Viral Vaccines · Chikungunya Fever · Chikungunya Virus Infection
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of First Vaccination — 0; 1; 1; 0 participants
Chikungunya Virus Infection
Primary: Number of Participants With Solicited Adverse Events (AEs) — 15; 11 Participants
Encephalitis, Japanese B
Primary: Seroconversion Rate After Primary Vaccination — 100 percentage of seroconversion
Rift Valley Fever
Primary: Safety as Measured by the Number of Adverse Events — 22; 130 AEs
Ebola Viruses
Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants
Malaria · Malaria Vaccines
Primary: Anti-Circumsporozoite (Anti-CS) Antibody Concentrations, One Month Post Dose 3 of SB257049 (Primary Analysis) — 452.87; 422.49 EU/mL
Influenza
Primary: Cost for the Medical Management of Patients — 581; 661 USD
Japanese Encephalitis
Primary: Number of Participants With Treatment Emergent Adverse Events Following Vaccination With Either ChimeriVax™ JE or JE Inactivated Mouse Brain Derived Vaccine — 2; 2; 1; 0…
Zika Virus
Primary: Number of Participants With Solicited Local and General Adverse Events (AEs) — 10; 5; 8; 5 Participants
Dengue
Primary: Assess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection. — 3.00; 5.2; 4.7; 5.0 log10 RNA copies/mL/days